|
September 7, 2022
The links included in this News Alert, previously published on 9/02, were broken after publication. Please accept our apologies. The links below have been corrected. Also, some new and updated information is included, so be sure to review!
On August 16th, the Inflation Reduction Act of 2022 (IRA) was signed into law. The text of the bill is located here and includes changes that, among other things, would allow the government to negotiate drug prices and reform the Medicare Part D benefit. Since the bill was signed into law, BluePeak has received a number of questions from clients with Prescription Drug Plans (PDPs), Medicare Advantage Part D Plans (MAPDs), and Employer Group Waiver Plans (EGWPs) about how to implement the IRA.
CMS has not yet issued specific guidance on this topic and so, its expectations cannot yet be fully known. In the meantime, follow the below links for the latest and recently updated FAQs from BluePeak. As a reminder, this is a recap of the various relevant provisions of the IRA, the associated implementation questions BluePeak has received, and BluePeak’s professional opinion and advice.
Prescription Drug Pricing Reform Section of the Inflation Reduction Act of 2022
Frequently Asked Implementation Questions
| 
